Dasatinib + Quercetin (D+Q)

What is Dasatinib + Quercetin?

Dasatinib + Quercetin is the senolytic combination with the most human clinical evidence — by a significant margin. Where FOXO4-DRI has compelling preclinical data and zero human trials, D+Q has completed Phase I/II trials in multiple disease populations, with peer-reviewed publications showing reduced senescent cell burden in human tissue and improved functional outcomes. If you're approaching senolytics from an evidence-based standpoint, D+Q is the place to start.

Senolytics — compounds that selectively kill senescent cells — emerged as a therapeutic category from the Mayo Clinic labs of James Kirkland and Jan van Deursen. Their 2015 discovery that removing senescent cells from aged mice (using a suicide gene approach) produced dramatic improvements in physical function inspired the search for pharmacological senolytics. The Kirkland lab's computational screening identified dasatinib — a BCR-ABL tyrosine kinase inhibitor used for leukemia — as a potent senolytic that targets the pro-survival signaling networks senescent cells depend on. Quercetin emerged as a complementary senolytic with overlapping but distinct target coverage. Together, D+Q kills senescent cells more effectively and across more cell types than either alone.

The human evidence is concentrated in two landmark trials. The UMN-Mayo Clinic Phase I trial in idiopathic pulmonary fibrosis (IPF): 9 patients received oral D+Q for 3 weeks. Skin punch biopsies showed significant reductions in senescent cell markers (p16, p21) and SASP components, and physical function tests (6-minute walk, gait speed, chair stand) improved. The Mayo Clinic Phase II trial in diabetic kidney disease: D+Q reduced senescent cell burden in adipose tissue biopsies and improved eGFR and other functional markers. These are small trials — but they're human tissue data showing actual senescent cell reduction after D+Q treatment. No other senolytic has this.

The practical challenge: dasatinib requires a prescription and is expensive. It was developed for cancer treatment, and its off-label use for senolytics is not covered by insurance. Quercetin is freely available as a supplement. The intermittent dosing protocol (2–3 days per month or once quarterly) is designed to minimize dasatinib's side effect exposure while achieving senolytic clearance. For most biohackers, access to dasatinib is the rate-limiting factor.

How it works

How Senolytics Work — The Pro-Survival Network

Senescent cells survive despite their damaged state by upregulating pro-survival pathways — BCL-2 family proteins (BCL-2, BCL-XL, BCL-W), PI3K/AKT survival signaling, and MDM2 (a p53 inhibitor). These pathways collectively constitute the "senescent cell anti-apoptotic pathway" (SCAP) that prevents senescent cells from undergoing the apoptosis that would normally eliminate them. Senolytics target these survival mechanisms specifically in senescent cells — which are uniquely dependent on them — while leaving healthy cells relatively unaffected because healthy cells don't rely on SCAP to survive.

Dasatinib — Tyrosine Kinase and BCL-2 Inhibition

Dasatinib inhibits multiple tyrosine kinases including BCR-ABL, SRC family kinases, and others. In the context of senescent cells, dasatinib's relevant targets include ephrin (EphB2/4) receptor kinases that support senescent cell survival, with downstream effects on BCL-2/BCL-XL anti-apoptotic proteins. Dasatinib is particularly effective against senescent fat cell progenitors (preadipocytes) and epithelial cells.

Quercetin — PI3K, MDM2, and BCL-XL

Quercetin inhibits PI3K (phosphoinositide 3-kinase), reduces MDM2 (which normally suppresses p53), and has BCL-XL inhibitory activity. PI3K inhibition reduces AKT survival signaling that senescent cells depend on; MDM2 reduction allows p53 to execute its apoptotic function. Quercetin is particularly effective against senescent human umbilical vein endothelial cells and natural killer cells — complementary to dasatinib's cell type coverage.

Complementary Coverage — Why the Combination Works

D+Q together cover the SCAP network more completely than either alone. Dasatinib targets kinase-driven survival; quercetin targets PI3K/p53/BCL-XL nodes. Different cell types are differentially sensitive to each compound. The combination produces synergistic senolytic activity across a broader range of senescent cell types than either compound alone — which is why Phase I testing moved directly to the combination rather than testing each separately.

What the research shows

What the community reports

The D+Q community in the biohacker space is smaller than FOXO4-DRI's — which benefits from a dramatic 2017 Cell paper — but more medically sophisticated. Users who choose D+Q over FOXO4-DRI typically do so specifically because of the human trial data.

Common misconceptions